A triple-transgenic immunotolerant mouse model.

Area of Science:

• Biotechnology
• Immunology
• Pharmacology

Background:

• Therapeutic drug proteins often elicit unwanted immunogenicity, limiting their efficacy.
• Existing animal models have limited predictive value and cannot assess combination products.
• Developing immunotolerant models is crucial for evaluating drug safety and manufacturing processes.

Purpose of the Study:

• To create a novel animal model for assessing the impact of manufacturing and formulation changes on immunogenicity.
• To develop a model suitable for evaluating both single protein and combination therapeutic products.
• To establish immunotolerance to multiple human coagulation factors in a single animal model.

Main Methods:

• Constructed two lines of transgenic mice using a single vector containing encoding sequences for human coagulation factors II, VII, and X.
• Utilized insulator sequences from the chicken beta-globin locus to separate the encoding sequences within the vector.
• Administered immunization protocols to transgenic mice and wild-type littermates for comparative analysis.

Main Results:

• Transgenic mice from both lines demonstrated immunotolerance to the expressed human coagulation factors II, VII, and X.
• Wild-type littermates exhibited expected immune responses, confirming the specificity of the immunotolerance in transgenic mice.
• The developed model successfully showed tolerance to multiple co-expressed proteins.

Conclusions:

• Transgenic mice can be successfully engineered to be immunotolerant to multiple therapeutic proteins.
• This novel animal model is potentially valuable for assessing immunogenicity related to manufacturing changes in drug development.
• The model's suitability for combination products addresses a significant limitation in current preclinical assessment strategies.